MX2022015800A - Metodos de uso de inhibidores de la quinasa rho para tratar demencia vascular. - Google Patents

Metodos de uso de inhibidores de la quinasa rho para tratar demencia vascular.

Info

Publication number
MX2022015800A
MX2022015800A MX2022015800A MX2022015800A MX2022015800A MX 2022015800 A MX2022015800 A MX 2022015800A MX 2022015800 A MX2022015800 A MX 2022015800A MX 2022015800 A MX2022015800 A MX 2022015800A MX 2022015800 A MX2022015800 A MX 2022015800A
Authority
MX
Mexico
Prior art keywords
methods
rho kinase
preferred
kinase inhibitors
vascular dementia
Prior art date
Application number
MX2022015800A
Other languages
English (en)
Spanish (es)
Inventor
Sven Jacobson
Thomas Macallister
Original Assignee
Woolsey Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Woolsey Pharmaceuticals Inc filed Critical Woolsey Pharmaceuticals Inc
Publication of MX2022015800A publication Critical patent/MX2022015800A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2022015800A 2020-06-15 2021-01-08 Metodos de uso de inhibidores de la quinasa rho para tratar demencia vascular. MX2022015800A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063039141P 2020-06-15 2020-06-15
US202063046173P 2020-06-30 2020-06-30
PCT/US2021/012590 WO2021257122A1 (en) 2020-06-15 2021-01-08 Methods of using rho kinase inhibitors to treat vascular dementia

Publications (1)

Publication Number Publication Date
MX2022015800A true MX2022015800A (es) 2023-01-24

Family

ID=79268240

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015800A MX2022015800A (es) 2020-06-15 2021-01-08 Metodos de uso de inhibidores de la quinasa rho para tratar demencia vascular.

Country Status (7)

Country Link
US (1) US20230285409A1 (https=)
EP (1) EP4164652A4 (https=)
JP (1) JP2023530120A (https=)
CN (1) CN116249532A (https=)
CA (1) CA3180411A1 (https=)
MX (1) MX2022015800A (https=)
WO (1) WO2021257122A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240423998A1 (en) 2021-11-29 2024-12-26 Woolsey Pharmaceuticals, Inc. Methods of treating agitation and other dementia-associated behavioral symptoms
WO2024243197A2 (en) * 2023-05-24 2024-11-28 Woolsey Pharmaceuticals, Inc. Method of treating patients with notch3 mutations
WO2025024104A2 (en) * 2023-07-06 2025-01-30 Woolsey Pharmaceuticals, Inc. Method for reducing caregiver burden associated with alzheimer's disease
WO2025101834A1 (en) * 2023-11-10 2025-05-15 Woolsey Pharmaceuticals, Inc. Methods of treating sporadic cerebral small vessel disease
CN119954776A (zh) * 2025-03-03 2025-05-09 中国药科大学 一种法舒地尔二氯乙酸盐的制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005117896A1 (de) * 2004-06-03 2005-12-15 Schering Aktiengesellschaft Formulierungen, die fasudil, eine matrix und einem mantel enthalten
WO2008019395A2 (en) * 2006-08-10 2008-02-14 Translational Genomics Research Institute Compounds for improving learning and memory
US8648069B2 (en) * 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
EP2285217A4 (en) * 2008-05-12 2011-06-08 Amnestix Inc CONNECTIONS TO IMPROVE LEARNING AND MEMORY
RU2014104690A (ru) * 2011-08-12 2015-09-20 Е.Р.Д.Е.-ААК-Диагностик ГмбХ АГОНИСТИЧЕСКИЕ АУТОАНТИТЕЛА К α1- И β2-АДРЕНЕРГИЧЕСКИМ РЕЦЕПТОРАМ ПРИ БОЛЕЗНИ АЛЬЦГЕЙМЕРА И СОСУДИСТОЙ ДЕМЕНЦИИ
WO2013066151A1 (en) * 2011-10-31 2013-05-10 N.V. Nutricia Improving recognition
US20150297679A1 (en) * 2012-12-14 2015-10-22 The Brigham And Women's Hospital, Inc. Methods and assays relating to macrophage differentiation
MX2022008513A (es) * 2020-01-09 2022-08-08 Woolsey Pharmaceuticals Inc Metodos para tratar la deambulacion asociada con la demencia cortical.
US20230080958A1 (en) * 2020-02-10 2023-03-16 Woolsey Pharmaceuticals, Inc. Methods of treating pseudobulbar affect and other emotional disturbances

Also Published As

Publication number Publication date
US20230285409A1 (en) 2023-09-14
CN116249532A (zh) 2023-06-09
CA3180411A1 (en) 2021-12-23
WO2021257122A1 (en) 2021-12-23
EP4164652A4 (en) 2024-07-10
JP2023530120A (ja) 2023-07-13
EP4164652A1 (en) 2023-04-19

Similar Documents

Publication Publication Date Title
MX2022015800A (es) Metodos de uso de inhibidores de la quinasa rho para tratar demencia vascular.
MX2022012957A (es) Metodos de uso de inhibidores de la quinasa rho para tratar la enfermedad de alzheimer.
Schnider et al. Long‐term outcome of patients with headache and drug abuse after inpatient withdrawal: five‐year follow‐up
MX2025012306A (es) Inhibidores del gen de sarcoma de rata de kirsten (kras) de 2-azabiciclo [2.2.1] heptano
CR20240059A (es) Compuestos tricíclicos como inhibidores de kras.
PH12022552739A1 (en) Fused tricyclic kras inhibitors
MX2024004444A (es) Compuestos de quinolina como inhibidores de la proteina del virus de sarcoma de rata kirsten (kras).
WO2021243280A3 (en) Methods of treating cancer in patients with an anomalous kras gene or deletions within chromosome 9
CR20210563A (es) Compuestos y métodos para el tratamiento de covid-19
Kontaxakis et al. Randomized controlled augmentation trials in clozapine-resistant schizophrenic patients: a critical review
Jenkins et al. The evidence for symptomatic treatments in amyotrophic lateral sclerosis
MXPA05003550A (es) Incremento de dosificacion y dosis diaria dividida de anti-depresivos para tratar padecimientos neurologicos.
NO20065676L (no) Forebyggelse av arteriell restenose med aktive vitamin D forbindelser.
Cohen et al. Allopurinol use during pediatric acute lymphoblastic leukemia maintenance therapy safely corrects skewed 6‐mercaptopurine metabolism, improving inadequate myelosuppression and reducing gastrointestinal toxicity
MX2022012310A (es) Metodos para tratar la esclerosis multiple recidivante con un inhibidor de tirosina quinasa de bruton.
JP2023523706A5 (https=)
MX2025000469A (es) Métodos y sistemas para el tratamiento de enfermedades mediante el uso de un inhibidor de la vía de señalización atr/chk1.
Prasko et al. Augmentation of antidepressants with bright light therapy in patients with comorbid depression and borderline personality disorder
ZA202307921B (en) Combination of raf inhibitor and mek inhibitor
MX2022012923A (es) Inhibidores de trpc6 para tratar afecciones respiratorias.
CL2022002317A1 (es) Métodos para tratar esclerosis múltiple progresiva primaria usando un inhibidor de tirosina quinasa de bruton.
Tadros et al. Anxiety disorders, PTSD and OCD: systematic review of approved psychiatric medications (2008–2024) and pipeline phase III medications
MX2023002165A (es) Metodos para tratar el deterioro cognitivo relacionado con la edad.
Nash et al. SAT0293 Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study
Likhitsathian et al. Cognitive changes in topiramate‐treated patients with alcoholism: a 12‐week prospective study in patients recently detoxified